Podcast Index
Parcourez les podcasts par catégorie, ouvrez les épisodes récents et téléchargez l’audio pour l’écouter hors ligne.
Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders
David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist
The Secret Teachings
Ryan Gable
Berretín de Tango
Berretín de Tango
The Amp Hour
David L. Jones and Chris Gammell
Trashologinnen - Reality-TV psychologisch analysiert
Dinah & Franzi
La Mano Peluda
Radio Fórmula
Somewhere in the Skies
SpectreVision Radio
Well... That’s Interesting
Jill ChaCha
Biotech Bytes: Conversations with Biotechnology / Pharmaceutical IT Leaders
Steve Swan
Kraken Cans Cast: Cryptids, Urban Legends, and All Things Spooky
Kraken Cans Crew
JP Lovecraft's Creepy Podcast
JP Lovecraft
Daily Paper Cast
Jingwen Liang, Gengyu Wang
Health Beyond Weight Loss |Insulin Resistance, Blood Sugar, Brain fog, Natural Remedies, Keto, Faith
TaShawn Davis, RN Holistic Health Coach, Author, Speaker
Radio Naukowe
Radio Naukowe - Karolina Głowacka
Artificial Intelligence Masterclass
AI Masterclass
After Skool
After Skool
Quazi Johir
Quazi Johir
La Science, CQFD
France Culture
The Grave Talks | Haunted, Paranormal & Supernatural
Ghost Stores, Haunted, Paranormal & Supernatural Stories
Real Ghost Stories Online
Real Ghost Stories Online | Paranormal, Supernatural & Horror Radio
NTVG PODCAST
Nederlands Tijdschrift Voor Geneeskunde
Daily Astrocat: Your Playful and Profound Daily Astrology Podcast!
Shane Jinson, Original backing tracks by Cabbitha.
Pharma and BioTech Daily
Pharma and BioTech News
Digimasters Shorts
Adam Nagus, Carly Wilson
Hyde Park Civilizace
Česká televize
Agents of the Inquisition: A Warhammer 40K RPG
Dumb-Dumbs & Dice
Rebel Road
Mary Rust & Haley Austill
Auditory Anthology
Keith Conrad / Darren Marlar
Engines of Our Ingenuity
Houston Public Media
Understand All
Aaron Barlow
The Biblical Hitmen
Stephen DeMatties Jr
Rambam Yomi
Rav Yoel Usher Labin and Rav Yitzchok Lowy
The Pulse
WHYY
Weather Wisdom
Dave Epstein
The Incubator
Ben Courchia & Daphna Yasova Barbeau
Security Cryptography Whatever
Deirdre Connolly, Thomas Ptacek, David Adrian
من الموسوعة العسكرية
Alsumood Podcast
Science
David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist
The cell and gene therapy industry faces massive hurdles—cost, scalability, and the need for highly skilled operators have historically limited the reach of these transformative treatments. advanced therapy medicinal pro...
What if the simple act of opening an incubator could undermine the consistency of your cell therapy manufacturing process? Unlike traditional biologics, the moment cells leave their incubator, subtle shifts in temperatur...
Digital transformation in biotech is no longer just about adopting new tools, it's about building a foundation where automation, data standardization, and AI integration actually lead to real value and long-term success....
Despite cutting-edge equipment and brilliant minds, biotech labs often find half their data trapped in difficult-to-access spreadsheets or isolated in silos, making true digital transformation a major, industry-wide hurd...
Host David Brühlmann returns for a focused solo episode to provide an honest, data-driven perspective on the evolving landscape of host selection for biologics manufacturing. Building on part one, David reviews five alte...
In this solo episode, David Brühlmann explores the evolving landscape of biologic manufacturing platforms beyond CHO (Chinese hamster ovary) cells. Drawing from previous interviews with platform pioneers and rigorous dat...
Funding novel therapeutics isn’t just “harder than ever”—the rules have changed entirely. The wild rush of capital into early-stage biotech during 2020–2021 gave way to a drought, making investor priorities sharper and s...
Strong science alone won’t get your biotech startup funded—investors are sizing up much more than just your molecule.Michael Rome, who leads therapeutics investing at Foresite Capital, brings a rare dual lens as both sci...
What happens between scientific discovery and clinical trials? For too many drug candidates, the answer is “failure”—not because the idea lacked merit, but because the critical handoff between discovery and IND-enabling ...
The gap between a “drug” and a true “product” is where many therapies fail.Milan Tomic, biotech veteran, GMP manufacturing expert, and founder of Albrem, has spent 30 years turning promising science into scalable, execut...
The "data lake" that was supposed to unify bioprocessing intelligence has, in most companies, become something else entirely: a data swamp, where information goes in and insight rarely comes back out. For anyone trying t...
When AI can draft a literature review in minutes, the question bioprocess educators can no longer avoid is this: what does a student actually need to learn?Steffen Kreye has a clear answer. As Professor of Industrial Bio...
Can aging be fundamentally slowed or even reversed—not by science fiction, but by harnessing the unassuming power of super-early stem cells?In Part 1, Yuta Lee, Founder and CEO of Accelerated Bio, walked through the biol...
What if the key to scalable, off-the-shelf cell therapy was hiding in tissue that surgeons discard every day?Yuta Lee, Founder and CEO of Accelerated Bio, has spent two decades building a cell therapy platform on exactly...
Are you still using one-factor-at-a-time experiments for biosimilar development, losing months, missing interactions, and risking costly dead-ends?In this episode, David Brühlmann, host of the Smart Biotech Scientist Pod...
Are you stuck screening endless compounds in biosimilar development and still not hitting your quality targets? Efficient compound screening is one of the toughest bottlenecks in biopharma, with outdated methods slowing ...
When every batch belongs to a single patient, a single centralized facility cannot serve the world. In Part 2, Chantale Bernatchez moves from process development into the broader consequences of that reality: the manufac...
The most underappreciated parameter in cell therapy process development is not your bioreactor, your media, or your activation protocol. It is the patient. Chantale Bernatchez has spent 20 years learning that lesson the ...
Getting an NDA signed shouldn't take weeks. If your CRO needs more than 48 hours to start the paperwork, your project timeline is already moving in the wrong direction.Ron Najafi knows what rigorous analytical work actua...
When drug safety fails, patients and entire markets pay the price. Understanding your CMC isn't just compliance — it's the line between therapeutic promise and product recall.Ron Najafi has lived that reality firsthand. ...
Remplissez le formulaire ci-dessous. Veillez à sélectionner à la fois Pays et Genres.
Envoyez-nous un message ci-dessous. Nous vous répondrons dans les 24 heures.